nodes	percent_of_prediction	percent_of_DWPC	metapath
Fentanyl—Quinapril—Lisinopril—systemic scleroderma	0.245	0.512	CrCrCtD
Fentanyl—Benazepril—Lisinopril—systemic scleroderma	0.233	0.488	CrCrCtD
Fentanyl—ABCB1—Lisinopril—systemic scleroderma	0.046	0.218	CbGbCtD
Fentanyl—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0417	0.197	CbGbCtD
Fentanyl—ABCB1—Captopril—systemic scleroderma	0.0345	0.163	CbGbCtD
Fentanyl—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0271	0.128	CbGbCtD
Fentanyl—ABCB1—Prednisone—systemic scleroderma	0.0217	0.103	CbGbCtD
Fentanyl—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0163	0.077	CbGbCtD
Fentanyl—CYP3A4—Prednisone—systemic scleroderma	0.013	0.0615	CbGbCtD
Fentanyl—ABCB1—Methotrexate—systemic scleroderma	0.0109	0.0515	CbGbCtD
Fentanyl—Quinapril—ACE—systemic scleroderma	0.000846	0.535	CrCbGaD
Fentanyl—Benazepril—ACE—systemic scleroderma	0.000736	0.465	CrCbGaD
Fentanyl—Breast disorder—Methotrexate—systemic scleroderma	8.72e-05	0.000282	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	8.7e-05	0.000281	CcSEcCtD
Fentanyl—Anxiety—Mycophenolate mofetil—systemic scleroderma	8.7e-05	0.000281	CcSEcCtD
Fentanyl—Hypersensitivity—Azathioprine—systemic scleroderma	8.67e-05	0.00028	CcSEcCtD
Fentanyl—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	8.67e-05	0.00028	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	8.67e-05	0.00028	CcSEcCtD
Fentanyl—Insomnia—Lisinopril—systemic scleroderma	8.64e-05	0.000279	CcSEcCtD
Fentanyl—Discomfort—Mycophenolate mofetil—systemic scleroderma	8.63e-05	0.000279	CcSEcCtD
Fentanyl—Paraesthesia—Lisinopril—systemic scleroderma	8.58e-05	0.000277	CcSEcCtD
Fentanyl—Vomiting—Captopril—systemic scleroderma	8.58e-05	0.000277	CcSEcCtD
Fentanyl—Dry mouth—Mycophenolate mofetil—systemic scleroderma	8.54e-05	0.000276	CcSEcCtD
Fentanyl—Dyspnoea—Lisinopril—systemic scleroderma	8.52e-05	0.000275	CcSEcCtD
Fentanyl—Rash—Captopril—systemic scleroderma	8.51e-05	0.000275	CcSEcCtD
Fentanyl—Dermatitis—Captopril—systemic scleroderma	8.5e-05	0.000274	CcSEcCtD
Fentanyl—Somnolence—Lisinopril—systemic scleroderma	8.49e-05	0.000274	CcSEcCtD
Fentanyl—Headache—Captopril—systemic scleroderma	8.45e-05	0.000273	CcSEcCtD
Fentanyl—Confusional state—Mycophenolate mofetil—systemic scleroderma	8.44e-05	0.000273	CcSEcCtD
Fentanyl—Dyspepsia—Lisinopril—systemic scleroderma	8.41e-05	0.000272	CcSEcCtD
Fentanyl—Abdominal pain—Mycophenolic acid—systemic scleroderma	8.39e-05	0.000271	CcSEcCtD
Fentanyl—Body temperature increased—Mycophenolic acid—systemic scleroderma	8.39e-05	0.000271	CcSEcCtD
Fentanyl—Oedema—Mycophenolate mofetil—systemic scleroderma	8.37e-05	0.00027	CcSEcCtD
Fentanyl—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	8.37e-05	0.00027	CcSEcCtD
Fentanyl—Asthma—Methotrexate—systemic scleroderma	8.34e-05	0.000269	CcSEcCtD
Fentanyl—Infection—Mycophenolate mofetil—systemic scleroderma	8.32e-05	0.000269	CcSEcCtD
Fentanyl—Decreased appetite—Lisinopril—systemic scleroderma	8.31e-05	0.000268	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Lisinopril—systemic scleroderma	8.25e-05	0.000266	CcSEcCtD
Fentanyl—Fatigue—Lisinopril—systemic scleroderma	8.24e-05	0.000266	CcSEcCtD
Fentanyl—Shock—Mycophenolate mofetil—systemic scleroderma	8.24e-05	0.000266	CcSEcCtD
Fentanyl—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.21e-05	0.000265	CcSEcCtD
Fentanyl—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.2e-05	0.000265	CcSEcCtD
Fentanyl—Hypersensitivity—Leflunomide—systemic scleroderma	8.19e-05	0.000265	CcSEcCtD
Fentanyl—Pain—Lisinopril—systemic scleroderma	8.17e-05	0.000264	CcSEcCtD
Fentanyl—Constipation—Lisinopril—systemic scleroderma	8.17e-05	0.000264	CcSEcCtD
Fentanyl—Tachycardia—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000264	CcSEcCtD
Fentanyl—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.13e-05	0.000263	CcSEcCtD
Fentanyl—Bradycardia—Prednisone—systemic scleroderma	8.13e-05	0.000263	CcSEcCtD
Fentanyl—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	8.09e-05	0.000261	CcSEcCtD
Fentanyl—Diarrhoea—Azathioprine—systemic scleroderma	8.06e-05	0.00026	CcSEcCtD
Fentanyl—Haemoglobin—Prednisone—systemic scleroderma	8.03e-05	0.000259	CcSEcCtD
Fentanyl—Nausea—Captopril—systemic scleroderma	8.01e-05	0.000259	CcSEcCtD
Fentanyl—Abdominal discomfort—Methotrexate—systemic scleroderma	7.99e-05	0.000258	CcSEcCtD
Fentanyl—Haemorrhage—Prednisone—systemic scleroderma	7.99e-05	0.000258	CcSEcCtD
Fentanyl—Anorexia—Mycophenolate mofetil—systemic scleroderma	7.98e-05	0.000258	CcSEcCtD
Fentanyl—Asthenia—Leflunomide—systemic scleroderma	7.98e-05	0.000258	CcSEcCtD
Fentanyl—Hallucination—Prednisone—systemic scleroderma	7.95e-05	0.000257	CcSEcCtD
Fentanyl—Pancytopenia—Methotrexate—systemic scleroderma	7.92e-05	0.000256	CcSEcCtD
Fentanyl—Feeling abnormal—Lisinopril—systemic scleroderma	7.87e-05	0.000254	CcSEcCtD
Fentanyl—Pruritus—Leflunomide—systemic scleroderma	7.87e-05	0.000254	CcSEcCtD
Fentanyl—Connective tissue disorder—Prednisone—systemic scleroderma	7.85e-05	0.000253	CcSEcCtD
Fentanyl—Hypotension—Mycophenolate mofetil—systemic scleroderma	7.82e-05	0.000253	CcSEcCtD
Fentanyl—Gastrointestinal pain—Lisinopril—systemic scleroderma	7.81e-05	0.000252	CcSEcCtD
Fentanyl—Dysuria—Methotrexate—systemic scleroderma	7.8e-05	0.000252	CcSEcCtD
Fentanyl—Neutropenia—Methotrexate—systemic scleroderma	7.8e-05	0.000252	CcSEcCtD
Fentanyl—Dizziness—Azathioprine—systemic scleroderma	7.79e-05	0.000251	CcSEcCtD
Fentanyl—Upper respiratory tract infection—Methotrexate—systemic scleroderma	7.75e-05	0.00025	CcSEcCtD
Fentanyl—Erectile dysfunction—Methotrexate—systemic scleroderma	7.68e-05	0.000248	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	7.63e-05	0.000246	CcSEcCtD
Fentanyl—Asthenia—Mycophenolic acid—systemic scleroderma	7.61e-05	0.000246	CcSEcCtD
Fentanyl—Diarrhoea—Leflunomide—systemic scleroderma	7.61e-05	0.000246	CcSEcCtD
Fentanyl—Urticaria—Lisinopril—systemic scleroderma	7.59e-05	0.000245	CcSEcCtD
Fentanyl—Insomnia—Mycophenolate mofetil—systemic scleroderma	7.57e-05	0.000245	CcSEcCtD
Fentanyl—Body temperature increased—Lisinopril—systemic scleroderma	7.55e-05	0.000244	CcSEcCtD
Fentanyl—Abdominal pain—Lisinopril—systemic scleroderma	7.55e-05	0.000244	CcSEcCtD
Fentanyl—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	7.52e-05	0.000243	CcSEcCtD
Fentanyl—Pruritus—Mycophenolic acid—systemic scleroderma	7.5e-05	0.000242	CcSEcCtD
Fentanyl—Vomiting—Azathioprine—systemic scleroderma	7.49e-05	0.000242	CcSEcCtD
Fentanyl—Pneumonia—Methotrexate—systemic scleroderma	7.48e-05	0.000242	CcSEcCtD
Fentanyl—Eye disorder—Prednisone—systemic scleroderma	7.46e-05	0.000241	CcSEcCtD
Fentanyl—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	7.46e-05	0.000241	CcSEcCtD
Fentanyl—Somnolence—Mycophenolate mofetil—systemic scleroderma	7.44e-05	0.00024	CcSEcCtD
Fentanyl—Infestation NOS—Methotrexate—systemic scleroderma	7.44e-05	0.00024	CcSEcCtD
Fentanyl—Drowsiness—Methotrexate—systemic scleroderma	7.44e-05	0.00024	CcSEcCtD
Fentanyl—Infestation—Methotrexate—systemic scleroderma	7.44e-05	0.00024	CcSEcCtD
Fentanyl—Rash—Azathioprine—systemic scleroderma	7.42e-05	0.00024	CcSEcCtD
Fentanyl—Dermatitis—Azathioprine—systemic scleroderma	7.42e-05	0.00024	CcSEcCtD
Fentanyl—Depression—Methotrexate—systemic scleroderma	7.41e-05	0.000239	CcSEcCtD
Fentanyl—Flushing—Prednisone—systemic scleroderma	7.41e-05	0.000239	CcSEcCtD
Fentanyl—Headache—Azathioprine—systemic scleroderma	7.38e-05	0.000238	CcSEcCtD
Fentanyl—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	7.37e-05	0.000238	CcSEcCtD
Fentanyl—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.000238	CcSEcCtD
Fentanyl—Dizziness—Leflunomide—systemic scleroderma	7.35e-05	0.000237	CcSEcCtD
Fentanyl—Renal failure—Methotrexate—systemic scleroderma	7.31e-05	0.000236	CcSEcCtD
Fentanyl—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.28e-05	0.000235	CcSEcCtD
Fentanyl—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.26e-05	0.000234	CcSEcCtD
Fentanyl—Stomatitis—Methotrexate—systemic scleroderma	7.25e-05	0.000234	CcSEcCtD
Fentanyl—Angiopathy—Prednisone—systemic scleroderma	7.25e-05	0.000234	CcSEcCtD
Fentanyl—Conjunctivitis—Methotrexate—systemic scleroderma	7.23e-05	0.000233	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.23e-05	0.000233	CcSEcCtD
Fentanyl—Immune system disorder—Prednisone—systemic scleroderma	7.21e-05	0.000233	CcSEcCtD
Fentanyl—Pain—Mycophenolate mofetil—systemic scleroderma	7.16e-05	0.000231	CcSEcCtD
Fentanyl—Constipation—Mycophenolate mofetil—systemic scleroderma	7.16e-05	0.000231	CcSEcCtD
Fentanyl—Arrhythmia—Prednisone—systemic scleroderma	7.14e-05	0.00023	CcSEcCtD
Fentanyl—Sweating—Methotrexate—systemic scleroderma	7.13e-05	0.00023	CcSEcCtD
Fentanyl—Haematuria—Methotrexate—systemic scleroderma	7.09e-05	0.000229	CcSEcCtD
Fentanyl—Vomiting—Leflunomide—systemic scleroderma	7.07e-05	0.000228	CcSEcCtD
Fentanyl—Alopecia—Prednisone—systemic scleroderma	7.06e-05	0.000228	CcSEcCtD
Fentanyl—Hypersensitivity—Lisinopril—systemic scleroderma	7.04e-05	0.000227	CcSEcCtD
Fentanyl—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.03e-05	0.000227	CcSEcCtD
Fentanyl—Dizziness—Mycophenolic acid—systemic scleroderma	7.01e-05	0.000227	CcSEcCtD
Fentanyl—Epistaxis—Methotrexate—systemic scleroderma	7.01e-05	0.000227	CcSEcCtD
Fentanyl—Rash—Leflunomide—systemic scleroderma	7.01e-05	0.000226	CcSEcCtD
Fentanyl—Dermatitis—Leflunomide—systemic scleroderma	7e-05	0.000226	CcSEcCtD
Fentanyl—Mental disorder—Prednisone—systemic scleroderma	7e-05	0.000226	CcSEcCtD
Fentanyl—Nausea—Azathioprine—systemic scleroderma	6.99e-05	0.000226	CcSEcCtD
Fentanyl—Headache—Leflunomide—systemic scleroderma	6.97e-05	0.000225	CcSEcCtD
Fentanyl—Malnutrition—Prednisone—systemic scleroderma	6.95e-05	0.000225	CcSEcCtD
Fentanyl—Erythema—Prednisone—systemic scleroderma	6.95e-05	0.000225	CcSEcCtD
Fentanyl—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	6.9e-05	0.000223	CcSEcCtD
Fentanyl—Asthenia—Lisinopril—systemic scleroderma	6.86e-05	0.000221	CcSEcCtD
Fentanyl—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	6.85e-05	0.000221	CcSEcCtD
Fentanyl—Pruritus—Lisinopril—systemic scleroderma	6.76e-05	0.000218	CcSEcCtD
Fentanyl—Vomiting—Mycophenolic acid—systemic scleroderma	6.74e-05	0.000218	CcSEcCtD
Fentanyl—Haemoglobin—Methotrexate—systemic scleroderma	6.71e-05	0.000217	CcSEcCtD
Fentanyl—Rash—Mycophenolic acid—systemic scleroderma	6.69e-05	0.000216	CcSEcCtD
Fentanyl—Dermatitis—Mycophenolic acid—systemic scleroderma	6.68e-05	0.000216	CcSEcCtD
Fentanyl—Haemorrhage—Methotrexate—systemic scleroderma	6.68e-05	0.000216	CcSEcCtD
Fentanyl—Urticaria—Mycophenolate mofetil—systemic scleroderma	6.65e-05	0.000215	CcSEcCtD
Fentanyl—Headache—Mycophenolic acid—systemic scleroderma	6.65e-05	0.000215	CcSEcCtD
Fentanyl—Pharyngitis—Methotrexate—systemic scleroderma	6.62e-05	0.000214	CcSEcCtD
Fentanyl—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	6.62e-05	0.000214	CcSEcCtD
Fentanyl—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	6.62e-05	0.000214	CcSEcCtD
Fentanyl—Nausea—Leflunomide—systemic scleroderma	6.6e-05	0.000213	CcSEcCtD
Fentanyl—Urinary tract disorder—Methotrexate—systemic scleroderma	6.59e-05	0.000213	CcSEcCtD
Fentanyl—Vision blurred—Prednisone—systemic scleroderma	6.55e-05	0.000212	CcSEcCtD
Fentanyl—Urethral disorder—Methotrexate—systemic scleroderma	6.54e-05	0.000211	CcSEcCtD
Fentanyl—Diarrhoea—Lisinopril—systemic scleroderma	6.54e-05	0.000211	CcSEcCtD
Fentanyl—Ill-defined disorder—Prednisone—systemic scleroderma	6.45e-05	0.000208	CcSEcCtD
Fentanyl—Visual impairment—Methotrexate—systemic scleroderma	6.43e-05	0.000208	CcSEcCtD
Fentanyl—Anaemia—Prednisone—systemic scleroderma	6.43e-05	0.000208	CcSEcCtD
Fentanyl—Agitation—Prednisone—systemic scleroderma	6.39e-05	0.000206	CcSEcCtD
Fentanyl—Dizziness—Lisinopril—systemic scleroderma	6.32e-05	0.000204	CcSEcCtD
Fentanyl—Erythema multiforme—Methotrexate—systemic scleroderma	6.31e-05	0.000204	CcSEcCtD
Fentanyl—Nausea—Mycophenolic acid—systemic scleroderma	6.3e-05	0.000204	CcSEcCtD
Fentanyl—Malaise—Prednisone—systemic scleroderma	6.27e-05	0.000203	CcSEcCtD
Fentanyl—Vertigo—Prednisone—systemic scleroderma	6.25e-05	0.000202	CcSEcCtD
Fentanyl—Eye disorder—Methotrexate—systemic scleroderma	6.24e-05	0.000201	CcSEcCtD
Fentanyl—Syncope—Prednisone—systemic scleroderma	6.24e-05	0.000201	CcSEcCtD
Fentanyl—Tinnitus—Methotrexate—systemic scleroderma	6.22e-05	0.000201	CcSEcCtD
Fentanyl—Cardiac disorder—Methotrexate—systemic scleroderma	6.2e-05	0.0002	CcSEcCtD
Fentanyl—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.000199	CcSEcCtD
Fentanyl—Loss of consciousness—Prednisone—systemic scleroderma	6.11e-05	0.000197	CcSEcCtD
Fentanyl—Vomiting—Lisinopril—systemic scleroderma	6.07e-05	0.000196	CcSEcCtD
Fentanyl—Angiopathy—Methotrexate—systemic scleroderma	6.06e-05	0.000196	CcSEcCtD
Fentanyl—Immune system disorder—Methotrexate—systemic scleroderma	6.03e-05	0.000195	CcSEcCtD
Fentanyl—Rash—Lisinopril—systemic scleroderma	6.02e-05	0.000195	CcSEcCtD
Fentanyl—Convulsion—Prednisone—systemic scleroderma	6.02e-05	0.000195	CcSEcCtD
Fentanyl—Dermatitis—Lisinopril—systemic scleroderma	6.02e-05	0.000194	CcSEcCtD
Fentanyl—Mediastinal disorder—Methotrexate—systemic scleroderma	6.02e-05	0.000194	CcSEcCtD
Fentanyl—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.01e-05	0.000194	CcSEcCtD
Fentanyl—Hypertension—Prednisone—systemic scleroderma	6e-05	0.000194	CcSEcCtD
Fentanyl—Chills—Methotrexate—systemic scleroderma	5.99e-05	0.000193	CcSEcCtD
Fentanyl—Headache—Lisinopril—systemic scleroderma	5.99e-05	0.000193	CcSEcCtD
Fentanyl—Pruritus—Mycophenolate mofetil—systemic scleroderma	5.92e-05	0.000191	CcSEcCtD
Fentanyl—Myalgia—Prednisone—systemic scleroderma	5.92e-05	0.000191	CcSEcCtD
Fentanyl—Arthralgia—Prednisone—systemic scleroderma	5.92e-05	0.000191	CcSEcCtD
Fentanyl—Anxiety—Prednisone—systemic scleroderma	5.9e-05	0.000191	CcSEcCtD
Fentanyl—Alopecia—Methotrexate—systemic scleroderma	5.9e-05	0.000191	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.88e-05	0.00019	CcSEcCtD
Fentanyl—Discomfort—Prednisone—systemic scleroderma	5.85e-05	0.000189	CcSEcCtD
Fentanyl—Mental disorder—Methotrexate—systemic scleroderma	5.85e-05	0.000189	CcSEcCtD
Fentanyl—Malnutrition—Methotrexate—systemic scleroderma	5.81e-05	0.000188	CcSEcCtD
Fentanyl—Erythema—Methotrexate—systemic scleroderma	5.81e-05	0.000188	CcSEcCtD
Fentanyl—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	5.73e-05	0.000185	CcSEcCtD
Fentanyl—Dysgeusia—Methotrexate—systemic scleroderma	5.69e-05	0.000184	CcSEcCtD
Fentanyl—Nausea—Lisinopril—systemic scleroderma	5.68e-05	0.000183	CcSEcCtD
Fentanyl—Anaphylactic shock—Prednisone—systemic scleroderma	5.67e-05	0.000183	CcSEcCtD
Fentanyl—Oedema—Prednisone—systemic scleroderma	5.67e-05	0.000183	CcSEcCtD
Fentanyl—Infection—Prednisone—systemic scleroderma	5.64e-05	0.000182	CcSEcCtD
Fentanyl—Back pain—Methotrexate—systemic scleroderma	5.62e-05	0.000182	CcSEcCtD
Fentanyl—Shock—Prednisone—systemic scleroderma	5.58e-05	0.00018	CcSEcCtD
Fentanyl—Nervous system disorder—Prednisone—systemic scleroderma	5.56e-05	0.00018	CcSEcCtD
Fentanyl—Tachycardia—Prednisone—systemic scleroderma	5.54e-05	0.000179	CcSEcCtD
Fentanyl—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.54e-05	0.000179	CcSEcCtD
Fentanyl—Skin disorder—Prednisone—systemic scleroderma	5.51e-05	0.000178	CcSEcCtD
Fentanyl—Hyperhidrosis—Prednisone—systemic scleroderma	5.49e-05	0.000177	CcSEcCtD
Fentanyl—Vision blurred—Methotrexate—systemic scleroderma	5.48e-05	0.000177	CcSEcCtD
Fentanyl—Anorexia—Prednisone—systemic scleroderma	5.41e-05	0.000175	CcSEcCtD
Fentanyl—Ill-defined disorder—Methotrexate—systemic scleroderma	5.39e-05	0.000174	CcSEcCtD
Fentanyl—Anaemia—Methotrexate—systemic scleroderma	5.37e-05	0.000173	CcSEcCtD
Fentanyl—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.32e-05	0.000172	CcSEcCtD
Fentanyl—Rash—Mycophenolate mofetil—systemic scleroderma	5.28e-05	0.00017	CcSEcCtD
Fentanyl—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.27e-05	0.00017	CcSEcCtD
Fentanyl—Headache—Mycophenolate mofetil—systemic scleroderma	5.24e-05	0.000169	CcSEcCtD
Fentanyl—Malaise—Methotrexate—systemic scleroderma	5.24e-05	0.000169	CcSEcCtD
Fentanyl—Vertigo—Methotrexate—systemic scleroderma	5.22e-05	0.000169	CcSEcCtD
Fentanyl—Leukopenia—Methotrexate—systemic scleroderma	5.2e-05	0.000168	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.17e-05	0.000167	CcSEcCtD
Fentanyl—Insomnia—Prednisone—systemic scleroderma	5.13e-05	0.000166	CcSEcCtD
Fentanyl—Paraesthesia—Prednisone—systemic scleroderma	5.1e-05	0.000165	CcSEcCtD
Fentanyl—Cough—Methotrexate—systemic scleroderma	5.07e-05	0.000164	CcSEcCtD
Fentanyl—Convulsion—Methotrexate—systemic scleroderma	5.03e-05	0.000163	CcSEcCtD
Fentanyl—Dyspepsia—Prednisone—systemic scleroderma	5e-05	0.000161	CcSEcCtD
Fentanyl—Nausea—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000161	CcSEcCtD
Fentanyl—Myalgia—Methotrexate—systemic scleroderma	4.95e-05	0.00016	CcSEcCtD
Fentanyl—Arthralgia—Methotrexate—systemic scleroderma	4.95e-05	0.00016	CcSEcCtD
Fentanyl—Chest pain—Methotrexate—systemic scleroderma	4.95e-05	0.00016	CcSEcCtD
Fentanyl—Decreased appetite—Prednisone—systemic scleroderma	4.93e-05	0.000159	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.91e-05	0.000159	CcSEcCtD
Fentanyl—Fatigue—Prednisone—systemic scleroderma	4.89e-05	0.000158	CcSEcCtD
Fentanyl—Discomfort—Methotrexate—systemic scleroderma	4.89e-05	0.000158	CcSEcCtD
Fentanyl—Constipation—Prednisone—systemic scleroderma	4.85e-05	0.000157	CcSEcCtD
Fentanyl—Confusional state—Methotrexate—systemic scleroderma	4.78e-05	0.000154	CcSEcCtD
Fentanyl—Anaphylactic shock—Methotrexate—systemic scleroderma	4.74e-05	0.000153	CcSEcCtD
Fentanyl—Infection—Methotrexate—systemic scleroderma	4.71e-05	0.000152	CcSEcCtD
Fentanyl—Feeling abnormal—Prednisone—systemic scleroderma	4.68e-05	0.000151	CcSEcCtD
Fentanyl—Nervous system disorder—Methotrexate—systemic scleroderma	4.65e-05	0.00015	CcSEcCtD
Fentanyl—Thrombocytopenia—Methotrexate—systemic scleroderma	4.64e-05	0.00015	CcSEcCtD
Fentanyl—Gastrointestinal pain—Prednisone—systemic scleroderma	4.64e-05	0.00015	CcSEcCtD
Fentanyl—Skin disorder—Methotrexate—systemic scleroderma	4.61e-05	0.000149	CcSEcCtD
Fentanyl—Hyperhidrosis—Methotrexate—systemic scleroderma	4.58e-05	0.000148	CcSEcCtD
Fentanyl—Anorexia—Methotrexate—systemic scleroderma	4.52e-05	0.000146	CcSEcCtD
Fentanyl—Urticaria—Prednisone—systemic scleroderma	4.51e-05	0.000146	CcSEcCtD
Fentanyl—Abdominal pain—Prednisone—systemic scleroderma	4.49e-05	0.000145	CcSEcCtD
Fentanyl—Body temperature increased—Prednisone—systemic scleroderma	4.49e-05	0.000145	CcSEcCtD
Fentanyl—Hypotension—Methotrexate—systemic scleroderma	4.43e-05	0.000143	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.32e-05	0.00014	CcSEcCtD
Fentanyl—Insomnia—Methotrexate—systemic scleroderma	4.29e-05	0.000139	CcSEcCtD
Fentanyl—Paraesthesia—Methotrexate—systemic scleroderma	4.26e-05	0.000138	CcSEcCtD
Fentanyl—Dyspnoea—Methotrexate—systemic scleroderma	4.23e-05	0.000137	CcSEcCtD
Fentanyl—Somnolence—Methotrexate—systemic scleroderma	4.22e-05	0.000136	CcSEcCtD
Fentanyl—Hypersensitivity—Prednisone—systemic scleroderma	4.18e-05	0.000135	CcSEcCtD
Fentanyl—Dyspepsia—Methotrexate—systemic scleroderma	4.17e-05	0.000135	CcSEcCtD
Fentanyl—Decreased appetite—Methotrexate—systemic scleroderma	4.12e-05	0.000133	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.09e-05	0.000132	CcSEcCtD
Fentanyl—Fatigue—Methotrexate—systemic scleroderma	4.09e-05	0.000132	CcSEcCtD
Fentanyl—Asthenia—Prednisone—systemic scleroderma	4.07e-05	0.000131	CcSEcCtD
Fentanyl—Pain—Methotrexate—systemic scleroderma	4.06e-05	0.000131	CcSEcCtD
Fentanyl—Pruritus—Prednisone—systemic scleroderma	4.01e-05	0.00013	CcSEcCtD
Fentanyl—Feeling abnormal—Methotrexate—systemic scleroderma	3.91e-05	0.000126	CcSEcCtD
Fentanyl—Diarrhoea—Prednisone—systemic scleroderma	3.88e-05	0.000125	CcSEcCtD
Fentanyl—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.88e-05	0.000125	CcSEcCtD
Fentanyl—Urticaria—Methotrexate—systemic scleroderma	3.77e-05	0.000122	CcSEcCtD
Fentanyl—Dizziness—Prednisone—systemic scleroderma	3.75e-05	0.000121	CcSEcCtD
Fentanyl—Body temperature increased—Methotrexate—systemic scleroderma	3.75e-05	0.000121	CcSEcCtD
Fentanyl—Abdominal pain—Methotrexate—systemic scleroderma	3.75e-05	0.000121	CcSEcCtD
Fentanyl—Vomiting—Prednisone—systemic scleroderma	3.61e-05	0.000117	CcSEcCtD
Fentanyl—Rash—Prednisone—systemic scleroderma	3.58e-05	0.000116	CcSEcCtD
Fentanyl—Dermatitis—Prednisone—systemic scleroderma	3.57e-05	0.000115	CcSEcCtD
Fentanyl—Headache—Prednisone—systemic scleroderma	3.55e-05	0.000115	CcSEcCtD
Fentanyl—Hypersensitivity—Methotrexate—systemic scleroderma	3.49e-05	0.000113	CcSEcCtD
Fentanyl—Asthenia—Methotrexate—systemic scleroderma	3.4e-05	0.00011	CcSEcCtD
Fentanyl—Nausea—Prednisone—systemic scleroderma	3.37e-05	0.000109	CcSEcCtD
Fentanyl—Pruritus—Methotrexate—systemic scleroderma	3.36e-05	0.000108	CcSEcCtD
Fentanyl—Diarrhoea—Methotrexate—systemic scleroderma	3.24e-05	0.000105	CcSEcCtD
Fentanyl—Dizziness—Methotrexate—systemic scleroderma	3.14e-05	0.000101	CcSEcCtD
Fentanyl—Vomiting—Methotrexate—systemic scleroderma	3.02e-05	9.74e-05	CcSEcCtD
Fentanyl—Rash—Methotrexate—systemic scleroderma	2.99e-05	9.66e-05	CcSEcCtD
Fentanyl—Dermatitis—Methotrexate—systemic scleroderma	2.99e-05	9.65e-05	CcSEcCtD
Fentanyl—Headache—Methotrexate—systemic scleroderma	2.97e-05	9.6e-05	CcSEcCtD
Fentanyl—Nausea—Methotrexate—systemic scleroderma	2.82e-05	9.1e-05	CcSEcCtD
